Aardvark Therapeutics

Historical price data

Aardvark Therapeutics is a clinical-stage biotech focused on developing first-in-class, oral small-molecule therapies that inhibit hunger by targeting gut-brain signaling pathways. Its core achievement is the development of ARD-101, a compound designed to activate gut bitter taste receptors (TAS2Rs) to trigger local satiety hormone release, thereby suppressing hunger with minimal systemic exposure. The company's strategy involves initially targeting rare diseases with severe hyperphagia, such as Prader-Willi Syndrome and hypothalamic obesity, to establish proof-of-concept before expanding into the broader obesity market. Recent appointments of high-profile industry veterans to its board underscore its transition into late-stage clinical development.

Aardvark's platform develops oral small-molecule gut-brain therapeutics that activate bitter taste receptors (TAS2Rs) in the digestive tract to stimulate local release of satiety hormones, thereby suppressing hunger signals with minimal systemic exposure.

In rare hyperphagia (e.g., Prader-Willi), Aardvark faces limited competition with no approved pharmacotherapies, positioning ARD-101 as a potential first-in-class agent. In general obesity, it differentiates from dominant GLP-1 drugs through its oral, peripherally-acting, hunger-specific mechanism, but will face immense commercial and developmental competition from established players.